No Data
No Data
Needham Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $7
Needham analyst Gil Blum maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 40.1% and a
Buy Rating Affirmed: Taysha Gene Therapies' TSHA-102 Shows Promising Efficacy and Quality of Life Improvements in Rett Syndrome
Needham Reiterates Buy on Taysha Gene Therapies, Maintains $7 Price Target
Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Board Observer of Taysha Gene Therapies Picks Up 5.7% More Stock
Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit
No Data